Jessica E. Lockery

Mar 29, 2024 | digitalcommons.library.tmc.edu | John McNeil |John Mcneil |Mark Nelson |Robyn L. Woods |Jessica E. Lockery

BACKGROUND: In the primary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, now published in the Journal, we report that the daily use of aspirin did not provide a benefit with regard to the primary end point of disability-free survival among older adults. A numerically higher rate of the secondary end point of death from any cause was observed with aspirin than with placebo.